



## Advicenne 2021 Universal Registration Document made available

**Paris, 29 April 2022 – 6.00 pm CEST** – Advicenne (Euronext Growth Paris ALDVI - FR0013296746), a pharmaceutical company specializing in the development and commercialization of innovative treatments for those suffering from rare renal diseases, today announces that its 2021 Universal Registration Document has been filed with the French Autorité des Marchés Financiers (AMF).

The Universal Registration Document includes the annual report, the group management report, the Board of Directors' report on corporate governance and the Statutory Auditors' reports. It also contains a description of the share buyback program.

The Universal Registration Document is available on Advicenne's website ([www.advicenne.com](http://www.advicenne.com)) in the Investors/Financial Information section and on the AMF website ([www.amf-france.org](http://www.amf-france.org)).

### About Advicenne

Advicenne (Euronext Growth Paris ALDVI - FR0013296746) is a specialty pharmaceutical company founded in 2007, specializing in the development of innovative treatments in Nephrology. Its lead product Sibnaya<sup>TM</sup> (ADV7103) has received its Marketing Approval for distal renal tubular acidosis in EU and the UK. ADV7103 is currently in late-stage development in cystinuria in Europe and in dRTA and cystinuria in the US and in Canada. Headquartered in Paris, Advicenne, listed on the Euronext Paris stock exchange since 2017, has now been listed on Euronext Growth Paris since its transfer on March 30, 2022. **For additional information see:** <https://advicenne.com/>.

### CONTACTS

#### Advicenne

Didier Laurens, CEO

+33 (0)1 87 44 40 17

Email: [investors@advicenne.com](mailto:investors@advicenne.com)

#### Ulysse Communication

Media relations

Bruno Arabian

+33 (0)6 87 88 47 26

Email: [barabian@ulyссе-communication.com](mailto:barabian@ulyссе-communication.com)

#### Consilium Strategic Communications

Mary-Jane Elliott, Ashley Tapp, Davide Salvi

+44 (0)20 3709 5700

Email: [advicenne@consilium-comms.com](mailto:advicenne@consilium-comms.com)



## **Disclaimer**

*This press release contains certain forward-looking statements concerning Advicenne group and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Advicenne considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the 2021 Universal Registration Document filed with the French financial market authority on April 29, 2022 (a copy of which is available on [www.advicenne.com](http://www.advicenne.com)) and to the development of economic conditions, financial markets and the markets in which Advicenne operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Advicenne or not currently considered material by Advicenne. The occurrence of all or part of such risks could cause actual results, financial conditions, performance, or achievements of Advicenne to be materially different from such forward-looking statements. Advicenne expressly declines any obligation to update such forward-looking statements.*